Zafgen Inc (ZFGN) was Downgraded by FBR Capital to ” Mkt Perform” while Lowering the Price Target of the company shares to $ 5 from a previous price target of $20 . Earlier the firm had a rating of “Outperform ” on the company shares. FBR Capital advised their investors in a research report released on Jul 20, 2016.
On the company’s financial health, Zafgen Inc reported $-0.65 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 10, 2016. Analyst had a consensus of $-0.72.During the same quarter in the previous year, the company posted $-0.53 EPS.
Zafgen Inc (ZFGN) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $6.68 and reached the intraday high at $6.79. The bulls started the profit booking and pushed the shares to intraday low of $6.5501. The trading session was marked by a volume range of 3,52,118 shares exchanging hands. The 52-week high of the shares is $47.98 and the 52-week low is $5.34. The market cap of the company stands at $182 M and there are 2,72,72,261 shares in public circulation.
In a different news, on Oct 20, 2015, Dennis D Kim (Chief Medical Officer) sold 39,407 shares at $40.00 per share price. According to the SEC, on Sep 25, 2015, Kevin P Starr (director) sold 136,579 shares at $43.92 per share price. On Sep 22, 2015, Alicia Secor (Chief Commercial Officer) sold 26,256 shares at $41.05 per share price, according to the Form-4 filing with the securities and exchange commission.
Zafgen Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications including severe obesity in two rare diseases Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO) including craniopharyngioma-associated obesity and severe obesity. Beloranib is in Phase III stage of development for obesity and hyperphagia in patients with PWS; completed Phase II clinical trial for HIAO and is in Phase IIb stage of development for severe obesity in the general population. The Company’s other product candidate ZGN-839 is in pre-clinical development stage. The Company is also evaluating the additional MetAP2 inhibitors beyond Beloranib as potential development candidates for the treatment of severe obesity.